May 23, 2025

  • Pharmaceuticals
  • R&D

Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma)

TOKYO, May 23, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Verastem Oncology issued a press release on AVMAPKITM (generic name: avutometinib) about positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with standard-of-care chemotherapy in frontline metastatic pancreatic ductal adenocarcinoma on May 22, 2025. AVMAPKI was created by Chugai, and its clinical development is being conducted by Verastem Oncology.

Please refer to the link below for details of the Verastem Oncology’s press release:
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-updated-results-ramp-205

Trademarks used or mentioned in this release are protected by laws.

[PDF 234KB]

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp

Back